Tanja Meyer

Tanja Meyer, PhD has a long and varied work experience. Tanja began their career in 2012 as a Consultant, Life Sciences. In 2014, they were a Consultant for 4D Molecular Therapeutics and an Advisor for the Lean LaunchPad/I-Corps™ at NIH and the Lean LaunchPad program at UCSF. In 2015, they began working at Sangamo Therapeutics, Inc. in the roles of Associate Director, Business Development, Associate Director, Product Development and Management, and Senior Manager Project Management. In 2017, they became an Advisor for the California Life Science Institute (CLSI) Fellows All Start Team (FAST) Advisory Program. In 2019, they moved to BioMarin Pharmaceutical Inc. as Associate Director, Corporate Strategy & Business Development. In 2020, they became Director, Business & Corporate Development at Allogene Therapeutics. In 2021, they took on the role of VP, Business Development at Metagenomi. Most recently, in 2022, they began working as VP & Head, Corporate Strategy & Business Development for Ambagon Therapeutics.

Tanja Meyer, PhD has an extensive educational background. Tanja completed their Doctor of Philosophy (Ph.D.) in Molecular Medicine from UCSF / University of Erlangen-Nuremberg in 2008. Prior to that, they completed their Master of Science in Molecular Medicine from the University of Erlangen-Nuremberg in 2004. Tanja also completed their Bachelor of Science in Molecular Medicine from the University of Erlangen-Nuremberg in 2002. Tanja Meyer, PhD also attended The Julius Maximilians University of Würzburg in 1998-1999, studying Biology. Additionally, they have attended Harvard Business School Online, John Hopkins | Coursera, and Wharton | Coursera, obtaining certifications in Negotiation Mastery, Design and Interpretation of Clinical Trials, Decision-Making and Scenarios, Modeling Risk and Realities, Spreadsheets and Models, and Fundamentals of Quantitative Modeling.